Pomerantz Law Firm Investigates Potential Securities Fraud at Edgewise Therapeutics
Pomerantz Law Firm Investigates Potential Securities Fraud at Edgewise Therapeutics
Pomerantz LLP, a prominent law firm, is currently investigating possible claims on behalf of investors of Edgewise Therapeutics, Inc., commonly known as Edgewise, listed under the NASDAQ ticker EWTX. Investors who believe they may have been misled should promptly reach out to Danielle Peyton at Pomerantz for further guidance and potential participation in a class action lawsuit.
This investigation centers around concerns that Edgewise and some of its senior officers and directors may have engaged in securities fraud or other unlawful business practices. Such actions can undermine investor confidence and lead to severe financial repercussions for those involved.
On June 26, 2025, Edgewise released information regarding clinical trials for its leading drug candidate, sevasemten, aimed at treating Becker and Duchenne muscular dystrophies. Despite labeling the trial results as
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.